scholarly article | Q13442814 |
P819 | ADS bibcode | 2012PLoSO...741290C |
P356 | DOI | 10.1371/JOURNAL.PONE.0041290 |
P932 | PMC publication ID | 3432026 |
P698 | PubMed publication ID | 22952580 |
P5875 | ResearchGate publication ID | 230805131 |
P50 | author | Laurent Papazian | Q34574633 |
P2093 | author name string | Djillali Annane | |
Antoine Roch | |||
Gilles Capellier | |||
Samuel Limat | |||
Mariette Mercier | |||
Christophe Faisy | |||
Claire Charpentier | |||
Gilles Blasco | |||
Hélène Mockly | |||
Joel Cousson | |||
Thibault Desmettre | |||
P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
Ventilator-associated pneumonia | Q28212947 | ||
Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report | Q33433721 | ||
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription | Q33912931 | ||
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial | Q34020982 | ||
When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn? | Q35168966 | ||
Nosocomial pneumonia: epidemiology and infection control | Q36363712 | ||
Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 Tables | Q36578288 | ||
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults | Q37029217 | ||
Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. | Q37150599 | ||
Early- and late-onset pneumonia: is this still a useful classification? | Q37247789 | ||
Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. | Q37702585 | ||
The influence of infection on hospital mortality for patients requiring > 48 h of intensive care. | Q39659525 | ||
Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia | Q40273432 | ||
Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia | Q40698893 | ||
Systematic reviews: synthesis of best evidence for clinical decisions | Q40903544 | ||
A predictive risk index for nosocomial pneumonia in the intensive care unit | Q43310319 | ||
Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome | Q43521705 | ||
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial | Q43609282 | ||
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group | Q44145974 | ||
Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia | Q44547515 | ||
Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated Patients | Q46507066 | ||
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia | Q46842546 | ||
Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria | Q47731388 | ||
Early- and late-onset ventilator-associated pneumonia acquired in the intensive care unit: comparison of risk factors. | Q47824655 | ||
Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. | Q50972762 | ||
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. | Q51643088 | ||
Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. | Q51715668 | ||
Incidence and outcome of polymicrobial ventilator-associated pneumonia. | Q51717315 | ||
Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. | Q51861262 | ||
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. | Q53338170 | ||
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. | Q54146487 | ||
Ventilator-Associated Pneumonia | Q57237894 | ||
Biologically active products of complement and acute lung injury in patients with the sepsis syndrome | Q70665611 | ||
Community-acquired pneumonia | Q72077200 | ||
Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia | Q73923634 | ||
The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group | Q77293121 | ||
Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia | Q80036566 | ||
Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes | Q81515756 | ||
Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit | Q82995823 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pneumonia | Q12192 |
ventilator | Q813243 | ||
P304 | page(s) | e41290 | |
P577 | publication date | 2012-08-31 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment | |
P478 | volume | 7 |
Q30408712 | Antibiotic stewardship in the intensive care unit |
Q64115391 | Antibiotic use practice and predictors of hospital outcome among patients with systemic bacterial infection: Identifying targets for antibiotic and health care resource stewardship |
Q90086575 | Guidelines for Antibiotic Prescription in Intensive Care Unit |
Q35004845 | How to approach and treat VAP in ICU patients |
Q37602669 | Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. |
Q50606202 | Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. |
Q36078359 | Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society |
Q26768365 | Pseudomonas aeruginosa ventilator-associated pneumonia management |
Q52670587 | Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. |
Q57294589 | Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign |
Q24187768 | Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults |
Q47646167 | Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis |
Q40081236 | To which extent can we decrease antibiotic duration in critically ill patients? |
Q26862843 | Ventilator-associated pneumonia in the ICU |
Q38271775 | Ventilator-associated pneumonia: present understanding and ongoing debates |
Search more.